Biogen (BIIB +1.8%) moves up after its Q4 easily beat EPS estimates earlier this morning....
Tuesday, January 31, 2012, 10:45 AM ETBiogen (BIIB +1.8%) moves up after its Q4 easily beat EPS estimates earlier this morning. Earnings rose 25% Y/Y on faster than expected revenue growth, helped by a jump in sales of Tysabri and Avonex. The company guides lower for FY12 however, saying revenue growth is showing signs of slowing. It now anticipates low-to mid-single-digit revenue growth in 2012.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles